Alix-Panabières Catherine, Riethdorf Sabine, Pantel Klaus
University Medical Center, Lapeyronie Hospital, Montpellier, France.
Clin Cancer Res. 2008 Aug 15;14(16):5013-21. doi: 10.1158/1078-0432.CCR-07-5125.
Sensitive immunocytochemical and molecular assays allow the detection of single circulating tumor cells (CTC) in the peripheral blood and disseminated tumor cells (DTC) in the bone marrow as a common and easily accessible homing organ for cells released by epithelial tumors of various origins. The results obtained thus far have provided direct evidence that tumor cell dissemination starts already early during tumor development and progression. Tumor cells are frequently detected in the blood and bone marrow of cancer patients without clinical or even histopathologic signs of metastasis. The detection of DTC and CTC yields important prognostic information and might help to tailor systemic therapies to the individual needs of a cancer patient. In the present review, we provide a critical review of (a) the current methods used for detection of CTC/DTC and (b) data on the molecular characterization of CTC/DTC with a particular emphasis on tumor dormancy, cancer stem cell theory, and novel targets for biological therapies; and we pinpoint to (c) critical issues that need to be addressed to establish CTC/DTC measurements in clinical practice.
灵敏的免疫细胞化学和分子检测方法能够检测外周血中的单个循环肿瘤细胞(CTC)以及骨髓中的播散肿瘤细胞(DTC),骨髓是各种起源的上皮肿瘤释放的细胞常见且易于获取的归巢器官。目前获得的结果提供了直接证据,表明肿瘤细胞播散在肿瘤发生发展的早期阶段就已开始。在没有临床甚至组织病理学转移迹象的癌症患者的血液和骨髓中经常检测到肿瘤细胞。检测DTC和CTC可产生重要的预后信息,并可能有助于根据癌症患者的个体需求定制全身治疗方案。在本综述中,我们对(a)目前用于检测CTC/DTC的方法以及(b)关于CTC/DTC分子特征的数据进行了批判性综述,特别强调肿瘤休眠、癌症干细胞理论和生物治疗的新靶点;并且我们指出了(c)在临床实践中建立CTC/DTC检测需要解决的关键问题。